The Danish drugmaker’s latest trial setback intensifies its high-stakes rivalry with Eli Lilly in the booming obesity market.

Novo’s CagriSema shot was shown to be less effective than rival Lilly’s tirzepatide ...

Novo Nordisk stock fell over 16% Monday after it said its next-generation weight loss drug didn't meet its primary target.

Shares of Novo Nordisk (NVO 0.29%) sank 20% this week, according to data from S&P Global Market Intelligence. The drugmaker ...

The list price of Wegovy will be cut in half on January 1, 2027, plummeting from around $1,350 to $675 a month. The cost of ...

After its next-generation obesity asset CagriSema lost a head-to-head matchup with Eli Lilly’s Zepbound, Novo Nordisk is ...

Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures ...

Novo Nordisk is slashing the list prices of its flagship weight-loss and diabetes drugs, including Wegovy and Ozempic, by up ...

Novo Nordisk announced Tuesday it will be slashing the list price of its blockbuster GLP-1 medications, Ozempic, Wegovy and ...

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its Ozempic shot, originally developed to treat diabetes, could help trim their ...

COPENHAGEN, Feb 24 (Reuters) - Novo Nordisk and United Laboratories International said on Tuesday a Chinese mid-stage trial ...